Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.

ABSTRACT: Non-small cell lung cancer (NSCLC) is one of the most threatening malignancies to human health and life. In most cases, patients with NSCLC are already at an advanced stage when they are diagnosed. In recent years, lung cancer has made great progress in precision therapy, but the efficacy of immunotherapy is unstable, and its response rate varies from patient to patient. Several biomarkers have been proposed to predict the outcomes of immunotherapy, such as programmed cell death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB). Nevertheless, the detection assays are invasive and demanding on tumor tissue. To effectively predict the outcomes of immunotherapy, novel biomarkers are needed to improve the performance of conventional biomarkers. Liquid biopsy is to capture and detec

SUBMITTER: Yang Y 

PROVIDER: S-EPMC10066332 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature